Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.46 +8.5%	$0.38	$0.24 ▼ $2.53	$24.66M	0.9	572,244 shs	681,725 shs
CTXR Citius Pharmaceuticals	$1.33 -5.0%	$1.49	$0.65 ▼ $15.25	$23.82M	1.19	341,734 shs	2.36 million shs
IXHL Incannex Healthcare	$0.66 +6.6%	$0.49	$0.08 ▼ $3.12	$18.19M	7.67	147.08 million shs	83.22 million shs
LIAN LianBio	$0.06 +1.4%	$0.18	$0.27 ▼ $4.99	$6.21M	0.23	1.04 million shs	283,631 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	+8.45%	+27.88%	+25.52%	+14.62%	-74.55%
CTXR Citius Pharmaceuticals	-5.00%	-1.48%	-4.32%	+92.36%	-90.79%
IXHL Incannex Healthcare	+6.63%	+12.07%	-25.11%	+225.91%	-62.56%
LIAN LianBio	0.00%	-0.53%	+8.00%	-84.25%	-83.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	2.8638 of 5 stars	3.0	3.0	0.0	0.0	3.8	2.5	0.6
CTXR Citius Pharmaceuticals	2.7874 of 5 stars	3.3	4.0	0.0	0.0	2.2	0.8	1.3
IXHL Incannex Healthcare	0.2132 of 5 stars	0.0	2.0	0.0	0.0	2.4	0.8	0.0
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.00	Hold	$5.00	997.69% Upside
CTXR Citius Pharmaceuticals	2.50	Moderate Buy	$53.00	3,884.96% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
LIAN LianBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LIAN, IXHL, CTXR, and BCAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/13/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	2.43	N/A	N/A	($0.29) per share	-1.57
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$3.97 per share	N/A
IXHL Incannex Healthcare	$98K	197.93	N/A	N/A	$0.18 per share	3.66
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	11/6/2025 (Estimated)
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.06	N/A	N/A	-60.03%	-33.83%	N/A
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A

Latest LIAN, IXHL, CTXR, and BCAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q3 2025	CTXR Citius Pharmaceuticals	-$0.76	-$0.80	-$0.04	-$0.80	$1.92 million	$1.92 million
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	1.24	1.24
CTXR Citius Pharmaceuticals	N/A	0.47	0.14
IXHL Incannex Healthcare	N/A	2.12	2.12
LIAN LianBio	N/A	10.06	10.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
CTXR Citius Pharmaceuticals	16.88%
IXHL Incannex Healthcare	0.43%
LIAN LianBio	74.85%

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.22%
CTXR Citius Pharmaceuticals	10.70%
IXHL Incannex Healthcare	15.49%
LIAN LianBio	7.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.72 million	52.13 million	Optionable
CTXR Citius Pharmaceuticals	20	17.01 million	15.19 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable

LIAN, IXHL, CTXR, and BCAB Headlines

Recent News About These Companies

MeiraGTx Holdings PLC

May 3, 2025 | marketwatch.com

With Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisition

October 9, 2024 | fiercebiotech.comF

China's Zeekr prices US IPO at top of range to raise $441 million

May 10, 2024 | msn.com

Exclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source says

May 9, 2024 | msn.com

Why Is LianBio (LIAN) Stock Moving Today?

March 15, 2024 | investorplace.com

LianBio Announces Voluntarily Delisting from Nasdaq

February 28, 2024 | globenewswire.com

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

February 23, 2024 | seekingalpha.com

LianBio to shut down, return cash to investors

February 14, 2024 | biopharmadive.comB

LianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-Market

February 13, 2024 | markets.businessinsider.com

LianBio to Wind Down Operations, Declares Special Dividend

February 13, 2024 | marketwatch.com

LianBio Shares Gain After Co Announces Plans to Wind Down

February 13, 2024 | marketwatch.com

LianBio Announces Completion of Strategic Review

February 13, 2024 | finance.yahoo.com

B of A Securities Downgrades LianBio: Here's What You Need To Know

January 3, 2024 | markets.businessinsider.com

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

December 26, 2023 | markets.businessinsider.com

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

December 26, 2023 | finance.yahoo.com

Interest Is Growing for Smaller, More Speculative Names

December 20, 2023 | realmoney.thestreet.com

LianBio Announces Departure of Chief Financial Officer

December 20, 2023 | finance.yahoo.com

LianBio Names Stone as Interim CEO as Wang Resigns

December 19, 2023 | marketwatch.com

LianBio Announces Departure of Chief Executive Officer

December 19, 2023 | finance.yahoo.com

LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

December 6, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIAN, IXHL, CTXR, and BCAB Company Descriptions

BioAtla NASDAQ:BCAB

$0.46 +0.04 (+8.45%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.99%)

As of 08/29/2025 07:57 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Citius Pharmaceuticals NASDAQ:CTXR

$1.33 -0.07 (-5.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.33 0.00 (-0.30%)

As of 08/29/2025 07:44 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Incannex Healthcare NASDAQ:IXHL

$0.66 +0.04 (+6.63%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.15%)

As of 08/29/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

LianBio NASDAQ:LIAN

$0.06 +0.00 (+1.41%)

As of 08/29/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time